HIMS FRAUD CLASS ACTION: Hims & Hers Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by August 25 Legal Deadline (NYSE:HIMS)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firmBleichmar Fonti & Auld LLPannounces that a lawsuit has been filed against Hims & Hers Health, Inc.HIMSand certain of the Company's senior executives for potential violations of the federal securities laws.If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting:https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captionedSookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captionedYaghsizian v. Hims & Hers Health, Inc., et al., No. 25-cv-05321.Why was Hims & Hers Sued for Securities Fraud?Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a "long-term collaboration" starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide.As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations.The Stock Declines as the Truth is RevealedOn June 23, 2025, Novo Nordisk announced that it was terminating the partnership, "based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk" and alleged that Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs." On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025.Click here for more information:https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.What Can You Do?If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.Trending Investment OpportunitiesAdvertisementArrivedBuy shares of homes and vacation rentals for as little as $100.Get StartedWiserAdvisorGet matched with a trusted, local financial advisor for free.Get StartedPoint.comTap into your home's equity to consolidate debt or fund a renovation.Get StartedRobinhoodMove your 401k to Robinhood and get a 3% match on deposits.Get StartedAll representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.Submit your information by visiting:https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-actionOr contact:Ross Shikowitzross@bfalaw.com212-789-3619Why Bleichmar Fonti & Auld LLP?BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm byChambers USA,The Legal 500, andISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by theNational Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" byLawdragon, "Titans of the Plaintiffs' Bar" byLaw360and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.For more information about BFA and its attorneys, please visithttps://www.bfalaw.com.https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-actionAttorney advertising. Past results do not guarantee future outcomes.Loading...Loading...HIMSHims & Hers Health Inc$47.50-0.81%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum96.35Growth98.64QualityN/AValue10.62Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Posted In:NewsLegalPress Releases